Current therapies for Parkinson disease focus mainly on symptomatic relief, but gene therapy approaches may offer the prospect of halting or reversing the progress of the disease process itself. A recent study provides evidence that sustained delivery of glial cell line-derived neurotrophic factor to the nigrostriatal system provides neuroprotection and functional recovery in a primate model of Parkinson disease.
